Elan Licenses Its NanoCrystal Technology to Roche
"We are pleased that we are going to continue to work with Roche to apply our NanoCrystal technology to the formulation of this drug candidate," said Paul Breen, executive vice president, Global Services & Operations, Elan. "For more than 30 years, Elan has been working to meet the challenges of drug delivery and enhance the performance of drugs. By addressing poor water solubility through the use of NanoCrystal technology, Elan Pharma International Ltd. continues to play a role in furthering the development of drug candidates. In addition, our technology can help companies to differentiate their current therapies from the competition by creating more effective and convenient treatment options for patients."
In the agreement, Elan will provide Roche with formulation services and technology in exchange for research revenues, development milestones and royalties on sales of the product incorporating or made using NanoCrystal technology.
"We are pleased to bring our 2003 evaluation agreement with Elan to this next level and are enthusiastic about the potential of NanoCrystal technology," said Urs Saner, Roche's Head of Pharma Technical Development. "This agreement further strengthens our ability to deliver value for patients as we continue to develop innovative, differentiated medicines."